BCOP Updates 2023: Treatment Updates in mCRPC: PSMA-Directed Therapy

Type: IndividualFormat: On-demand

Men with metastatic castration-resistant prostate cancer (mCRPC) have limited treatment options. Prostate-specific membrane antigen (PSMA) is expressed in >80% of men with mCRPC. PluvictoTM (Lutetium Lu-177 vipivotide tetraxetan) is the first FDA-approved targeted radioligand treatment which combines a targeting ligand with a therapeutic radiaoactive particle for the treatment of mCRPC in adults who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy. Lu-177-PSMA-617 radionucleotide therapy has demonstrated significant improvement in overall survival (OS) and progression-free survival (PFS). With its novel mechanism of action and proven efficacy, Lu-177-PSMA-617 promises to change the treatment landscape in prostate cancer.

In this module, participants will review treatment options for mCRPC, with a focus on PSMA-directed therapy. This session will describe the novel mechanism of action of Lu-177-PSMA-617 and analyze key literature leading to its FDA-approval with an emphasis on safety and efficacy. At the end of this session, participants will be able to identify the role of Lu-177-PSMA-617 in the treatment of mCRPC and understand dosing/administration and access considerations for this treatment option.  This session will also review monitoring parameters and side effect management for PSMA-directed therapy.

Get it now!

System Requirements

All online, interactive modules require a computer and a reliable internet connection.

If you have questions about these modules, please contact HOPA Education at education@hoparx.org.

Accreditation Statement

The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by July 19, 2024.

The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of Board Certified Oncology Pharmacist (BCOP) credit. A BCOP statement of credit will be issued only upon completion of a post- activity evaluation form, and post-test, a passing grade of 75% or greater is achieved. BCOP credit must be claimed by July 19, 2024 .

Disclosure of Conflicts of Interest

The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.

Reported Areas of Conflict

The Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.

Get it now!